← Leaderboards
Ryo Kubota
Acucela, Inc.
$1,633,917
Attributed
$1,633,917
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $545K · FY2020–22$1M$750K$500K$250K$0
'20
'21
'22
Funding mix
By agency
FDA$1,633,917 · 1
By mechanism
R01$1,633,917 · 1
Top collaborators
No co-investigators on record.
Grant awards (3)
A Phase 3 Study of Emixustat Hydrochloride for Stargardt Disease IND 101,084 (02/11/2019)$545,000
R01 · FY2022 · FD · contact PI
A Phase 3 Study of Emixustat Hydrochloride for Stargardt Disease IND 101,084 (02/11/2019)$545,000
R01 · FY2021 · FD · contact PI
A Phase 3 Study of Emixustat Hydrochloride for Stargardt Disease IND 101,084 (02/11/2019)$543,917
R01 · FY2020 · FD · contact PI